若生智能
Drug Database
PA

pancrelipase (Ultrase MT20 / Ultrase MT / Ultresa)

✓ Approved

Adare Pharma Solutions · PNLIP

什么是 pancrelipase？

pancrelipase 是一种治疗药物，由Adare Pharma Solutions研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Ultrase MT20, Ultrase MT, Ultresa
公司Adare Pharma Solutions
分子靶点PNLIP
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Adare Pharma Solutions

作用机制

分子靶点

pancrelipase 作用于 1 个分子靶点：

PNLIPpancreatic lipase (PL, PNLIPD)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

pancrelipase 针对 3 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
InvestigationsFaecal fat increased✓ Approved
Gastrointestinal disordersSteatorrhoea✓ Approved
Gastrointestinal disordersPancreatic failure✓ Approved

相关研究文献

PubMedJournal of toxicology2026-08-05

Spatiotemporal Distribution, Risk, and Source Identification of Organochlorine Pesticides in the Surface Water of Shitalakshya River, Bangladesh.

Islam Md Mazharul MM, Shoeb Mohammad M, Mamun Md Iqbal Rouf MIR

This study investigates the spatiotemporal distribution of organochlorine pesticides (OCPs) in the surface water (n = 60) of Shitalakshya River, Bangladesh, by an optimized and validated LLE-GC-ECD method by calibration (0.10-5.00 µgL-1), linearity (R 2 = 0.995-0.999), recovery (80.11%-117.10%), precision, specificity, selectivity, LODs (0.0009-0.0026 µgL-1), and LOQs (0.0027-0.0079 µgL-1). Among the targeted OCPs, α-BHC (0.01-0.19 µgL-1), δ-BHC (0.01-0.27 µgL-1), chlordane (0.01-0.23 µgL-1), endosulfan (0.01 and 1.56 µgL-1), 4,4'-DDE (0.01-2.14 µgL-1), dieldrin (0.03-0.58 µgL-1), endrin (0.01-2.96 µgL-1), 4,4'-DDD (0.01-4.07 µgL-1), endrin aldehyde (0.01-3.72 µgL-1), 4,4'-DDT (0.01-0.02 µgL-1), and endosulfan sulfate (0.03-2.05 µgL-1) were detected with varying frequencies. These levels were below the international guideline values, except 4,4'-DDE in Kanchon (2.14 μgL-1), dieldrin in Kanchpur (0.10 μgL-1), Atlapur (0.12 μgL-1), Ghorashal (0.45 μgL-1), Charshindur (0.58 μgL-1) and Kapasia (0.03 μgL-1), endrin in Kapasia (2.96 μgL-1), 4,4'-DDD in Kalagachhia (1.63 μgL-1), Narayanganj (0.69 μgL-1), Nabiganj (1.95 μgL-1), Ichakhali (1.05 μgL-1), Kanchon (0.57 μgL-1), Atlapur (1.02 μgL-1), Ghorashal (2.51 μgL-1), and Charshindur (4.07 μgL-1). The occurrence of OCPs exhibited pronounced spatiotemporal variation, with the highest concentrations and detection frequencies observed during the dry seasons (L. autumn, autumn, winter, and spring), indicating reduced dilution and possible remobilization from contaminated sediments. Multivariate statistical analysis revealed distinct sources, with endosulfans and BHCs dominating at Kanchon, whereas dieldrin, endrin, and chlordane were more strongly associated with Ghorashal and nearby locations, suggesting localized anthropogenic inputs and legacy pollution sources. While risk is generally low, specific exceedances (H q  > 1) were observed in L. Autumn 2022 for 4,4'-DDD, indicating a localized noncarcinogenic hazard. While the immediate screening-level risks are low across most seasons, the high chemical persistence and bioaccumulation over time warrant continued monitoring and proactive water management.

PMID 42553604
阅读全文 →
PubMedInternational journal of clinical oncology2026-08-05

Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC.

Nishioka Naoya N, Murata Daiki D, Azuma Koichi K, Ito Kazuhiro K et al.

Thyroid transcription factor-1 (TTF-1) has emerged as a novel predictive biomarker associated with the prognosis and treatment response of non-squamous non-small-cell lung cancer (NSCLC) to cytotoxic chemotherapy. This study evaluated the clinical significance of TTF-1 expression in advanced NSCLC with programmed death-ligand 1 (PD-L1) < 1%, with a specific focus on its utility in stratifying treatment outcomes between dual immune checkpoint inhibitor (IO-IO) therapy and chemoimmunotherapy. We conducted a multicenter retrospective study across 22 Japanese institutions, evaluating 194 patients with advanced or recurrent non-squamous NSCLC and PD-L1 < 1% treated with IO-IO therapy or chemoimmunotherapy between 2019 and 2022. Survival outcomes were analyzed using multivariable Cox regression. TTF-1-positive patients had significantly longer progression-free survival (PFS) and overall survival (OS) than TTF-1-negative patients [adjusted hazard ratio (HR) for PFS: 0.65, p = 0.009; adjusted HR for OS: 0.69, p = 0.04]. Among TTF-1-positive patients, no significant difference in survival was observed between IO-IO therapy and chemoimmunotherapy. By contrast, TTF-1-negative patients experienced significantly improved outcomes with chemoimmunotherapy than with IO-IO therapy (adjusted HR for PFS: 0.37, p = 0.01; adjusted HR for OS: 0.39, p = 0.02). TTF-1 expression may serve as a prognostic and potentially predictive biomarker in PD-L1-negative NSCLC patients. TTF-1-negative patients appeared to derive greater benefit from the addition of chemotherapy. These findings suggest that TTF-1 expression may have potential utility in guiding treatment selection and warrant prospective validation.

PMID 42552404
阅读全文 →
PubMedBrain and behavior2026-08-05

Association of the TREM-1-STAT3 Axis With Stroke Severity and Functional Outcomes in Ischemic Stroke: A Prospective Case-Control Study.

Lin Haohai H, Dong Yan Y, He Zhangping Z, Qin Chao C et al.

Information regarding the signaling axis involving triggering receptor expressed on myeloid cells 1 (TREM-1) and its downstream mediator, signal transducer and activator of transcription 3 (STAT3), remains limited in ischemic stroke. We investigated the plasma levels of TREM-1 in patients with ischemic stroke and compared to controls. Second, we investigated the potential correlation between plasma TREM-1 levels and STAT3 expression in peripheral blood mononuclear cells (PBMCs) and explored their associations with stroke severity and functional outcomes. In an observational case-control study, plasma and PBMCs from participants were collected to measure TREM-1 and STAT3 expression levels. The National Institutes of Health Stroke Scale (NIHSS) at admission, day 7, and 1 and 3 months, and the modified Rankin Scale (mRS) at 3 months post-discharge were assessed. Plasma TREM-1 levels and STAT3 expression were measured by enzyme-linked immunosorbent assay (ELISA) and quantitative reverse transcription polymerase chain reaction (RT-qPCR), respectively. The Inflammation-Related Principal Component Score (IRPCS) was examined for its association with 3-month functional outcome. TREM-1 and STAT3 were significantly elevated in acute ischemic stroke (AIS) patients (p < 0.05, p < 0.0001) and positively correlated (ρ = 0.432, p < 0.0001). Both biomarkers correlated with the NIHSS at 1 and 3 months and mRS at 3 months (all p < 0.05). The composite IRPCS showed the strongest association with poor 3-month functional outcome among the tested biomarkers (OR = 2.84, 95% CI: 1.32-6.12, p = 0.008). Plasma TREM-1 levels were positively correlated with STAT3 expression. The TREM-1-STAT3 axis was associated with stroke severity and 3-month functional outcome in AIS patients. These findings should be regarded as exploratory and require validation in larger cohorts.

PMID 42552903
阅读全文 →
PubMedThe western journal of emergency medicine2026-08-05

9-1-1 Call Data Modeling to Assess the Influence of a Mass Gathering on Host Community Metrics for Syndromic Surveillance.

Yancey Arthur H AH, Robinson Elijah E, McMahan Timothy T, Cotsonis George A GA

Multi-day planned mass gatherings are prevalent in various forms of sports competitions, concerts, professional, political, and religious conferences. The largest, the World Cup competition, will be hosted by large cities of the United States, Canada, and Mexico in June and July, 2026. These can present risks to the health of spectators, participants, organizers, and host communities, which if discovered faster, facilitates more effective responses in preventing morbidity/mortality. This study demonstrates visually modeled 9-1-1 medical data that uniquely contributes to existing syndromic surveillance activities by its practicality and time sensitivity. Using data from the nine-day period of 2019 Super Bowl LIII festivities, this retrospective, quantitative, descriptive, population-based study was conducted to demonstrate how 9-1-1 emergency medical dispatch (EMD) data could be practically modeled to more rapidly detect changes from baseline host community 9-1-1 data. Our ultimate objective is to illustrate these visual models in the attempt to improve syndromic surveillance. All 9-1-1 medical calls from three host municipalities were processed and categorized at the Grady Emergency Medical Services (EMS) Communications Center during game day and eight preceding days of festivities (time frame-standardized to nine-day events period). This events period call volume was contrasted to that of the identical nine-day pre- and post-events periods. The mean 24 one-hour interval call volumes for each day of these three periods were analyzed. Data visualization techniques (a data table, bar graphs, geo-, and heat-mapping) were constructed to illustrate differences in 9-1-1 call volumes of three categories (hypothermia, traffic injury incidents, and violence-induced injuries), for the three periods. The most similar previous such studies were reviewed and related to our study. The events period call volume (3,267) was less than that in pre- (3,356) and post-(3,460) events totals. Directional (increasing versus decreasing) patterns in hourly call frequencies were similar among all three periods. Cold exposure calls decreased across the three periods (successive period were 9, 7, and 4 respectively). Changes in traffic incidents were minimal (36, 39, and 38, respectively). Violent act injury calls increased during the post-events period (151, 150, and 166, respectively). Data from 9-1-1 calls could provide readily discoverable trends reflective of clinically significant syndromes threatening host community health status associated with planned mass gatherings. The study demonstrates practical data modeling to enhance syndromic surveillance. Recommendations are offered for enhancing 9-1-1 data analysis in conducting syndromic surveillance.

PMID 42550722
阅读全文 →
PubMedBritish journal of cancer2026-08-05

A Phase 1/2 study of ontorpacept (TTI-621) in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma.

Movva Sujana S, Allgood Victoria V, Chugh Rashmi R, Davis Lara E LE et al.

Ontorpacept, a recombinant signal regulatory protein alpha (SIRPα)-blocking fusion protein, has antitumour activity by disrupting CD47-SIRPα signalling. This Phase 1/2 study examined ontorpacept with doxorubicin in patients with leiomyosarcoma. Eligible patients were ≥18 years with metastatic or locally advanced high-grade soft-tissue sarcomas (high-grade leiomyosarcoma in Phase 2). In Phase 1, patients received escalating doses of ontorpacept plus doxorubicin. Phase 2 dose expansion evaluated ontorpacept doses 0.2, 1.0, and 2.0 mg/kg plus doxorubicin. The primary endpoints were safety (Phase 1); and objective response rate (ORR) (Phase 1/2). Seventy-six patients were enrolled (Phase 1, n = 9; Phase 2, n = 67). No dose-limiting toxicities occurred in Phase 1. The most common treatment-related adverse events were neutrophil count decreased/neutropenia (grade ≥3 in 66% of patients). In Phase 1, one patient receiving ontorpacept 2.0 mg/kg had a confirmed partial response. In Phase 2, six patients receiving ontorpacept 0.2 mg/kg (ORR, 18.8%; 95% CI, 7.2-36.4) and one patient receiving 2.0 mg/kg (ORR, 4.5%; 95% CI, 0.1-22.8) had confirmed partial responses. This first study of CD47 inhibition with chemotherapy in leiomyosarcomas shows manageable safety, supporting further investigation of ontorpacept dosing and schedule, in combination with doxorubicin and as monotherapy.

PMID 42552364
阅读全文 →
PubMedThe CRISPR journal2026-08-05

Targeted Genetic Knockout of Can f 1, the Major Allergen in Dogs.

Walker Matt W G MWG, Margolis Carol C, Wiegand Tanner T, Gavin Nicholas N et al.

Dog allergy is a prevalent IgE-mediated condition, with the salivary lipocalin Can f 1 accounting for the majority of dog-specific IgE reactivity in sensitized individuals. Existing strategies for managing dog allergy primarily rely on modulating host immune responses and do not address allergen production at its source. Here, we report the generation of genetically engineered dogs lacking Can f 1. Using CRISPR-Cas9 editing and somatic cell nuclear transfer, we produced two healthy beagle puppies carrying a frameshift mutation in exon 1 of the Can f 1 gene. Salivary and hair/dander analysis demonstrated the absence of Can f 1 protein in the edited dogs. Skin prick testing in a sensitized individual demonstrated robust IgE-mediated reactivity to control dog extracts but no detectable response to extracts from the edited dogs. Together, these findings demonstrate that targeted genetic knockout of the major dog allergen is compatible with canine development and can abolish the IgE-mediated allergic response, supporting the feasibility of a gene-based approach to reducing canine allergenicity.

PMID 42554239
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多pancrelipase